Equillium, Inc. (EQ) Stock

Equillium, Inc. (EQ) is a Healthcare stock trading at $3.03 (as of 2026-06-18), with a market capitalization of $183.36M and a trailing P/E of -14.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Equillium, Inc. is a clinical-stage biotechnology company developing and selling therapies for severe autoimmune, inflammatory, and immuno-inflammatory disorders with unmet medical need. Its pipeline includes itolizumab (EQ001) targeting CD6, with programs in acute graft-versus-host disease and other immune-related diseases, plus additional candidates such as EQ101 and EQ102.

Valuation — source: SEC EDGAR (first-party)
Price	$3.03
Market Cap	$183.36M
P/E Ratio	-14.5
EV / EBITDA	-6.5
Price / Book	3.24
Price / Sales	199.01
DCF Value (model)	$-5.66
DCF Upside vs Price	-286.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$833000.00
Net Margin	-2688.8%
Return on Equity	-32.0%
Current Ratio	18.62
Revenue Growth (YoY)	-98.0%
EPS Growth (YoY)	69.6%
FCF Growth (YoY)	19.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	24.08 (safe)

Valuation vs Sector & Industry
Stock P/E	-14.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-169.5%
vs Industry	-185.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($12.96M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Bruce D. Steel
Employees	35
Country	US
IPO Date	2018-10-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.